NEW YORK, NY / ACCESSWIRE / March 28, 2017 / These two stocks posted gains on Monday as they are likely to reduce losses going ahead. Both companies also moved forward with the FDA trials as their lead candidates advanced to Phase II (a).

RDI Initiates Coverage:

BioDelivery Sciences International, Inc. https://ub.rdinvesting.com/news/?ticker=BDSI

Rexahn Pharmaceuticals, Inc. https://ub.rdinvesting.com/news/?ticker=RNN

BioDelivery Sciences International went up 8.57% to close at $1.90 on Monday. The stock traded between $1.90 and $1.76 on volume of 409,980 shares traded. The company, which develops pharmaceutical products that are primarily focused in the medical areas of pain management and addiction, has been trading at a relatively even level over the past 5 trading days. As the stock's price has remained relatively steady over the last five days, investors are hoping for some type of insider trading activity or other sign that the stock is prepared to make a consistent upwards move.

The company's total net revenue as reported on March 17th of this year, is in a best way comparable from a quarter-to-quarter comparison, as one time milestone payment from Endo significantly popped up its revenue in the same quarter last year. For the three-months ended December 31, 2016, its revenue was $3.9 million compared to $3.6 million for the quarter ended September 30, 2016. This slight loss is more representative of the company's financials, as it has reported $30 million of total $50 million payment in fourth quarter of 2015 for reaching the BELBUCA-related FDA approval milestone. BioDelivery has reported significant increase in products sales in the year 2016 as compared to those of year 2015 and with the reacquisition of worldwide rights of BELBUCA from Endo, BioDelivery looking to increase revenue and to bring its commercial operations to profitability. BioDelivery has also secured $75 million in debt financing from CRG to strengthen cash balance on their books.

Access RDI's BioDelivery Sciences Research Report at: https://ub.rdinvesting.com/news/?ticker=BDSI

Rexahn Pharmaceuticals advanced 13.33% to close at $0.51 on Monday. The stock traded between $0.52 and $0.44 per share on volume of 7,032,752 shares traded. The stock's daily trading graph mimics its 90 day trading graph, as it has shown consistent resiliency despite some bumps. Yesterday, the company released its 4th quarter financials, which revealed that the company lost from operations was $16.4 million, a reduction of $1.9 million from 2015.

For its ongoing FDA drug trial candidates, the company reported that 4 of its drugs were entering Phase 2 protocols: RX-3117 for pancreatic cancer, Archexin to treat renal cell carcinoma, RX-3117 used in advanced cases of bladder cancer, and has begun a regimen of its trademarked drug Supinoxin in treating breast cancer.

Access RDI's Rexahn Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=RNN

Our Actionable Research on BioDelivery Sciences International, Inc. (NASDAQ: BDSI) and Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com